Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Solasia Pharma KK ( (JP:4597) ).
Solasia Pharma reported a 35.4% year-on-year increase in consolidated sales to ¥429 million for the fiscal year ended December 31, 2025, while narrowing its operating loss to ¥861 million and net loss attributable to owners of the parent to ¥876 million. The company strengthened its financial position with total assets rising to ¥2,145 million, equity attributable to owners of the parent climbing to ¥1,752 million, and cash and cash equivalents increasing to ¥1,387 million on the back of positive financing cash flow, though it maintained a zero-dividend policy and withheld a forecast for 2026 due to difficulty in providing a reasonable outlook.
The most recent analyst rating on (JP:4597) stock is a Hold with a Yen29.00 price target. To see the full list of analyst forecasts on Solasia Pharma KK stock, see the JP:4597 Stock Forecast page.
More about Solasia Pharma KK
Solasia Pharma K.K. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange. The company focuses on developing and commercializing pharmaceutical products, with operations structured under International Financial Reporting Standards and a primary presence in the oncology and specialty care markets.
Average Trading Volume: 39,327,437
Technical Sentiment Signal: Sell
Current Market Cap: Yen8.6B
For an in-depth examination of 4597 stock, go to TipRanks’ Overview page.